drugset / Trial / NCT00110617
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
Timeline
- Start
- 2005-05
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferasirox | Unknown | 20 mg/kg | Oral |
| Subject | Deferoxamine | Other / unclassified | 175 mg/kg | Subcutaneous |